Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06482268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

Study acronym: CT1-DAP001
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 10 months later Feb 28, 2025 → Dec 28, 2027
Primary endpoint reworded 1 of 2 changed
See other at-risk trials from University of California, San Diego

Record History

  1. Primary completion pushed from Feb 28, 2025 to Dec 28, 2027 Primary endpoint(s) modified · Eligibility criteria revised · Secondary endpoints revised (6) · 2 morev6 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria revised
    • Secondary endpoints revised (6)
    • Site contact updated
    • Collaborators: 4 to 3

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria shortened, about 175 wordsv5 See this version in full on ClinicalTrials.gov ↗
  3. Eligibility criteria expanded, about 12 wordsv4 See this version in full on ClinicalTrials.gov ↗
  4. Collaborators: 2 to 4v3 See this version in full on ClinicalTrials.gov ↗
  5. Primary endpoints revised (2) Eligibility criteria expanded, about 447 words · Secondary endpoints: 2 to 6v2 Show 2 more changesShow less
    • Eligibility criteria expanded, about 447 words
    • Secondary endpoints: 2 to 6

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
Trial Details
NCT Number NCT06482268
Lead Sponsor University of California, San Diego
Collaborators: Sumitomo Pharma America, Inc., Kyoto University, Sumitomo Pharma Co., Ltd.
Conditions PD - Parkinson's Disease
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov